← All trials
NCT04617509
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2020
- Primary completion
- May 27, 2020
- Completion date
- May 27, 2020
- First posted
- Nov 5, 2020
- Last posted
- Nov 5, 2020
- Enrollment
- 14
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gesynta Pharma ABLead sponsor
- Clinical Trial Consultants ABOverall official - principal investigator
- Clinical Trial Consultants ABCollaborator
- Clinical Trial Consultants ABOverall official - principal investigator
- RISE Research Institutes of Sweden ABCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.